Immunopositivity for ESCRT-III subunit CHMP2B in granulovacuolar degeneration of neurons in the Alzheimer's disease hippocampus - PubMed (original) (raw)
. 2010 Jun 21;477(2):86-90.
doi: 10.1016/j.neulet.2010.04.038. Epub 2010 Apr 24.
Affiliations
- PMID: 20420883
- DOI: 10.1016/j.neulet.2010.04.038
Immunopositivity for ESCRT-III subunit CHMP2B in granulovacuolar degeneration of neurons in the Alzheimer's disease hippocampus
Yuu Yamazaki et al. Neurosci Lett. 2010.
Abstract
Endosomal sorting complex required for transport (ESCRT)-III subunit charged multivesicular body protein 2B (CHMP2B) is involved in the degradation of proteins in the endocytic and autophagic pathways. Mutations in the CHMP2B gene are reportedly associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) characterised by accumulation of ubiquitinated protein aggregates in affected neurons, suggesting a relationship between protein accumulation and efficient autophagic degradation. This study investigated CHMP2B immunoreactivity in the hippocampus of patients with Alzheimer's disease (AD), revealing intense labeling of intraneuronal dot-like structures by antibody to CHMP2B. Since the morphological characteristics of these granular structures were compatible with those of granulovacuolar degeneration (GVD), a hallmark of AD pathology, immunohistochemical study using anti-CHMP2B antibody was performed using AD and control brain sections to investigate whether this antibody can be used as a GVD label. The number and percentage of hippocampal neurons with CHMP2B-positive granules were higher in AD cases and CHMP2B-positive granules corresponded to GVD. Anti-CHMP2B antibody detected a single 28-kDa band on Western blotting using control and AD specimens. This antibody clearly and intensely detected GVD over the hippocampus and entorhinal and transentorhinal cortices. These findings suggest that researchers will be able to use CHMP2B as a molecular label for studying GVD.
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Effect of tau-pathology on charged multivesicular body protein 2b (CHMP2B).
Midani-Kurçak JS, Dinekov M, Puladi B, Arzberger T, Köhler C. Midani-Kurçak JS, et al. Brain Res. 2019 Mar 1;1706:224-236. doi: 10.1016/j.brainres.2018.11.008. Epub 2018 Nov 8. Brain Res. 2019. PMID: 30414727 - Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease.
Bondareff W, Wischik CM, Novak M, Roth M. Bondareff W, et al. Am J Pathol. 1991 Sep;139(3):641-7. Am J Pathol. 1991. PMID: 1909492 Free PMC article. - Localization of CHMP2B-immunoreactivity in the brainstem of Lewy body disease.
Kurashige T, Takahashi T, Yamazaki Y, Hiji M, Izumi Y, Yamawaki T, Matsumoto M. Kurashige T, et al. Neuropathology. 2013 Jun;33(3):237-45. doi: 10.1111/j.1440-1789.2012.01346.x. Epub 2012 Sep 19. Neuropathology. 2013. PMID: 22989140 - Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology.
Köhler C. Köhler C. Acta Neuropathol. 2016 Sep;132(3):339-59. doi: 10.1007/s00401-016-1562-0. Epub 2016 Apr 9. Acta Neuropathol. 2016. PMID: 27062260 Review.
Cited by
- ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways.
Oshima R, Hasegawa T, Tamai K, Sugeno N, Yoshida S, Kobayashi J, Kikuchi A, Baba T, Futatsugi A, Sato I, Satoh K, Takeda A, Aoki M, Tanaka N. Oshima R, et al. Sci Rep. 2016 Apr 26;6:24997. doi: 10.1038/srep24997. Sci Rep. 2016. PMID: 27112194 Free PMC article. - Tau-targeting therapies for Alzheimer disease: current status and future directions.
Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Congdon EE, et al. Nat Rev Neurol. 2023 Dec;19(12):715-736. doi: 10.1038/s41582-023-00883-2. Epub 2023 Oct 24. Nat Rev Neurol. 2023. PMID: 37875627 Free PMC article. Review. - Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology.
Wiersma VI, van Ziel AM, Vazquez-Sanchez S, Nölle A, Berenjeno-Correa E, Bonaterra-Pastra A, Clavaguera F, Tolnay M, Musters RJP, van Weering JRT, Verhage M, Hoozemans JJM, Scheper W. Wiersma VI, et al. Acta Neuropathol. 2019 Dec;138(6):943-970. doi: 10.1007/s00401-019-02046-4. Epub 2019 Aug 27. Acta Neuropathol. 2019. PMID: 31456031 Free PMC article. - A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules.
Castellani RJ, Gupta Y, Sheng B, Siedlak SL, Harris PL, Coller JM, Perry G, Lee HG, Tabaton M, Smith MA, Wang X, Zhu X. Castellani RJ, et al. Lab Invest. 2011 Dec;91(12):1777-86. doi: 10.1038/labinvest.2011.149. Epub 2011 Oct 3. Lab Invest. 2011. PMID: 21968813 Free PMC article. - The proteome of granulovacuolar degeneration and neurofibrillary tangles in Alzheimer's disease.
Hondius DC, Koopmans F, Leistner C, Pita-Illobre D, Peferoen-Baert RM, Marbus F, Paliukhovich I, Li KW, Rozemuller AJM, Hoozemans JJM, Smit AB. Hondius DC, et al. Acta Neuropathol. 2021 Mar;141(3):341-358. doi: 10.1007/s00401-020-02261-4. Epub 2021 Jan 25. Acta Neuropathol. 2021. PMID: 33492460 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous